We are excited to share the recent press release and BBC coverage of our study into genetic factors contributing to cancer drug related cardiomyopathy.
In this study, published in the journal Circulation, we analysed genes of more than 200 cancer patients from the UK, Spain and the US who had been diagnosed with a type of heart condition called cancer-therapy induced cardiomyopathy, or CCM. We found patients who developed the heart condition were more likely to carry genetic faults linked to cardiomyopathy – and in particular that patients were more likely to carry a faulty version of a gene called titin.